Effect of dutasteride on microvessel density in benign prostatic hyperplasia

Area of Science:

• Urology
• Histopathology
• Pharmacology

Background:

• Benign prostatic hyperplasia (BPH) is a common condition in aging men.
• Dutasteride, a 5α-reductase inhibitor, is a standard treatment for BPH.
• The precise histopathological effects of dutasteride on prostatic vasculature remain debated.

Purpose of the Study:

• To retrospectively evaluate the histopathological impact of dutasteride on prostatic morphometrics.
• To assess changes in microvessel density (MVD) in BPH patients treated with dutasteride.

Main Methods:

• Patients with BPH received either daily dutasteride (0.5 mg) or no treatment before holmium laser enucleation of the prostate (HoLEP).
• Prostatic tissue from the bladder neck and apex was collected post-HoLEP.
• Tissue sections were stained with hematoxylin/eosin and immunohistochemistry for CD31 to quantify MVD.

Main Results:

• The dutasteride group (n=14) showed a significantly lower MVD at the bladder neck compared to the control group (p=0.018).
• Mean treatment duration in the dutasteride group was 7.07±2.46 weeks.

Conclusions:

• Dutasteride effectively reduces MVD in the bladder neck region of the prostate in BPH patients.
• This reduction in MVD may contribute to a decreased risk of perioperative prostatic urethral bleeding.